Todd W Miller, PhD
Associate Professor of Molecular and Systems Biology
Director, PhD Program in Experimental & Molecular Medicine
Co-Director, Cancer Biology & Therapeutics Research Program, Norris Cotton Cancer Center
Scientific Director, Comprehensive Breast Program, Norris Cotton Cancer Center
Co-Director, Molecular Tumor Board, Norris Cotton Cancer Center
Molecular and Systems Biology
University of Connecticut (Storrs, CT), B.S., Physiology & Neurobiology, 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004
Vanderbilt University (Nashville, TN), Post-doctoral Fellowship in Breast Cancer, 2004-2009
Program in Experimental and Molecular Medicine
1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756
Office: Rubin 604
Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development
R01 CA200994 (PI: Miller) 04/01/2017 – 03/31/2022
A precision medicine basis for estrogen therapy for advanced breast cancer.
R01 CA211869 (PI: Miller)
09/04/2017 – 08/31/2022
A precision medicine basis for Pl3K inhibition in ER+ breast cancer.
Pilot Project Grant (PI: Miller) 08/01/2014 – no end
Norris Cotton Cancer Center Early-Phase Trials Program
Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.
Investigator-initiated Phase I clinical study (PI: Schwartz)
Takeda Pharmaceuticals 10/01/2015 – no end
Phase 1 study of combination of MLN9708 and Fulvestrant in patients with advanced ER+ breast cancer.
PEMM 102- Scientific Basis of Disease II
PEMM 126- Cancer Biology
PEMM 132- Clinical Management of Cancer
Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.
2012-2014 Lloye Dillon, Ph.D., Postdoctoral Fellow (Current Position: Senior Scientist, Research & Development, OncoTAb, Inc., Charlotte, NC)
2012-2018 Wei Yang, M.S., PhD Student (Current position: Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center)
2013-2018 Sarah Hosford, PhD Student (Current position: Scientist in In Vivo Pharmacology at Cobalt Biomedicine)
2014-2018 Kevin Shee, MD/PhD student (Current position: medical student at Geisel)
2015-present Riley Hampsch, PhD student
2016-present Nicole Traphagen, PhD student
2017-present Jason Wells, PhD student
2017-present Bianca Romo, PhD student
2018-present Jackie Griffin, PhD, Postdoctoral Fellow
Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.